In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development

Anti-Cancer Drug Design

Volumn 12, Issue 5, 1997, Pages 359-371

  Cowsert, Lex M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ISIS 2503; RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER; GENE MUTATION; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BASE SEQUENCE; GENE EXPRESSION REGULATION; GENES, RAS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RAS PROTEINS;

EID: 0030838791     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. ALTMANN, K.H., DEAN, N.M., FABBRO, D, FREIER, S.M., GEIGER, T., HANER, R., HUSKEN, D., MARTIN, P., MONIA, B.P., MULLER, M., NATT, F., NICKLIN, P, PHILLIPS, J., PIELES, U., SASMOR, H. & MOSER, H.E. (1996). Second generation of antisense oligonucleotides from nuclease resistance to biological efficacy in animals. Chimia, 50, 168.
2. AOKI, K., YOSHIDA, T., SUGIMURA, T & TERADA, M. (1995). Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Research, 55, 3810.
3. BARBACID, M. (1987). Ras genes. Annual Review of Biochemistry, 56, 779.
4. BENNETT, C.F., DEAN, N, ECKER, D.J. & MONIA, B.P. (1996). Pharmacology of Antisense Therapeutics Agents: Cancer and Inflammation. Humana Press: Totowa.
5. BISHOP, J.M. (1991). Molecular themes in oncogenesis. Cell, 64, 235.
6. BLACK, L.E., FARRELLY, J.G., CAVAGNARO, J.A., AHN C.H., DEGEORGE, J.J., TAYLOR, A.S., DEFELICE, A.F. & JORDAN, A. (1994). Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Research and Development, 4, 299.
7. BOGUSKI, M.S. & MCCORMICK, F. (1993). Proteins regulating Ras and its relatives. Nature, 366, 643.
8. BOKOCH, G.M. & DER, C.J. (1993). Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB Journal, 7, 750.
9. BOS, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Research, 49, 4682.
10. BOS, J.L., VERLAAN-DE VRIES, M., MARSHALL, C.J., VEENEMAN, G H., VAN BOOM, J.H.& VAN DER EB, A.J (1986). A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Research, 14, 1209.
11. CHANG, E.H., MILLER, P.S., CUSHMAH, C , DEVADAS, K, PIROLLO, K F., TS'O, PO. & YU, Z.P. (1991). Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry, 30, 8283.
12. CHEN, G., OH. S . MONIA, B.P. & STACEY, D.W. (1996). Antisense oligonucleotides demonstrate a dominant role of c-Ki-ras proteins in regulating the proliferation of diploid human fibroblasts. Journal of Biological Chemistry, 271, 28259.
13. CROOKE, R.M. (1991). In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Design, 6, 609.
14. CROOKE, S.T (1996a). Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Development, 6, 145.
15. CROOKE, ST (1996b). Progress in the development of antisense drugs. Expert Opinion on Investigational Drugs, 5, 1047.
16. CROOKE, S.T & BENNETT, C.F. (1996). Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology, 36, 107.
17. DUROUX, I , GODARD, G., BOIDOT-FORGET, M., SCHWAB, G., HELENE, C. & SAISON-BEHMOARAS, T. (1995). Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-ras mRNA in human cells. Nucleic Acids Research, 23, 3411.
18. FARNSWORTH, C L. & FEIG, L A. (1991). Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP. Molecular and Cellular Biology, 11, 4822.
19. FEIG, L.A. & COOPER, G.M (1988). Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Molecular and Cellular Biology, 8, 3235.
20. FEIG, L.A., PAN, B.T., ROBERTS, T.M. & COOPER, G M (1986). Isolation of ras GTP-binding mutants using an in situ colony-binding assay. Proceedings of the National Academy of Sciences of the USA, 83, 4607.
21. GEORGES, R N., MUKHOPADHYAY, T., ZHANG, Y, YEN, N. & ROTH, J.A. (1993). Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Research, 53, 1743.
22. GILES, R V. & TIDD, D M. (1992). Enhanced RNase H activity with methylphosphonodiester/ phosphodiester chimeric antisense oligodeoxynucleotides. Anticancer Drug Design, 7, 37.
23. GODARD, G., BOUTORINE, A.S , SAISON-BEHMOARAS, E. & HELENE, C. (1995). Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nano-particles. European Journal of Biochemistry, 232, 404.
24. GRAY, G D, HERNANDEZ, O.M., HEBEL, D., ROOT, M, POW-SANG, J.M. & WICKSTROM, E (1993). Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Research, 53, 577.
25. HALL, A. (1990a). The cellular functions of small GTP-binding proteins. Science, 249, 635.
26. HALL, A. (1990b). Ras and Gap - who's controlling whom? Cell, 61, 921.
27. IVERSEN, P.L., COPPLE, B.L. & TEWARY, H.K. (1995). Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters, 82, 425.
28. JAMES, G.L , GOLDSTEIN, J.L., BROWN, M.S., RAWSON, TE., SOMERS, T.C , MCDOWELL, R.S., CROWLEY, C.W , LUCAS, B.K , LEVINSON, A.D. & MARSTERS, J.C., JR (1993). Benzodiazepuie peptidomimetics: potent inhibitors of ras farnesylation in animal cells Science, 260, 1937.
29. JAMES, G.L., GOLDSTEIN, J.L. & BROWN, M.S. (1995). Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. Journal of Biological Chemistry, 270, 6221.
30. KNUDSON, A.G., JR (1977). Origins of Human Cancer. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
31. KOHL, N.E , WILSON, F R., MOSSER, S.D., GIULIANI, E , DESOLMS, S.J., CONNER, M.W., ANTHONY, N.J., HOLTZ, WJ , GOMEZ, R.P , LEE, T.J. ET AL. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proceedings of the National Academy of Sciences of the USA, 91, 9141.
32. KOHL. N.E., OMER, C.A., CONNER, M W., ANTHONY, N.J., DAVIDE, J.P., DESOLMS, S.J., GIULIANI, E.A., GOMEZ. R.P., GRAHAM, S.L , HAMILTON, K. ET AL, (1995). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice [see comments]. Nature Medicine, 1, 792.
33. LACAL, J. & TRONICK, S. (1991). The ras oncogene. In The Oncogene Handbook. Reddy, E., Skalka, A. & Curran T. (eds), p. 255. Elsevier Press: New York.
34. LIAO, Y, TANG, Z.Y, LIU, K.D., YE, S.L, & HUANG, Z (1997). Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA - in vitro and in vivo studies. Journal of Cancer Research and Clinical Oncology, 123, 25.
35. MANNE, V., YAN, N., CARBONI, J.M., TUOMARI, A.V., RICCA, C.S., BROWN. J.G., ANDAHAZY, M.L., SCHMIDT, R.J., PATEL, D., ZAHLER, R ET AL. (1995). Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene, 10, 1763.
36. MCCORMICK, F (1989). Ras GTPase activating protein: signal transmitter and signal terminator. Cell, 56, 5.
37. MONIA, B.P., JOHNSTON, J F., ECKER, D.J., ZOUNES, M A, LIMA, W.F & FREIER, S.M. (1992). Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. Journal of Biological Chemistry, 267, 19954.
38. MONIA, B P., LESNIK, E A., GONZALEZ, C., LIMA, WF., MCGEE. D , GUINOSSO, C.J., KAWASAKI, A.M., COOK. P.D. & FREIER, S.M. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry, 268, 14514.
39. MOOLGAVKAR, S. & KNUDSON, A.G. (1981). Mutation and cancer: a model for human carcinogenesis. Journal of the National Cancer Institute, 66, 1037.
40. MUKHOPADHYAY, T., TAINSKY, M., CAVENDER, A.C. & ROTH, J.A, (1991). Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Research, 51, 1744.
41. MULCAHY, L.S., SMITH, M.R &. STACEY D.W (1985). Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature, 313, 241.
42. OVERBECK, A.F., BRTVA, T.R., COX, A D , GRAHAM, S M., HUFF, S.Y., KHOSRAVI-FAR, R., QUlLLIAM, L A., SOLSKI, PA. & DER, C.J (1995). Guanine nucleotide exchange factors: activators of ras super family proteins. Molecular and Reproductive Development, 42, 468.
43. POWERS, S, O'NEILL, K. & WIGLER. M (1989). Dominant yeast and mammalian ras mutants that interfere with the CDC25-dependent activation of wild-type ras in Saccharomyces cerevisiae. Molecular and Cellular Biology, 9, 390.
44. POWERS, S., GONZALES, E , CHRISTENSEN, T. CUBERT, J & BROEK. D (1991). Functional cloning of BUD5, a CDC25-related gene from S. cerevisiae that can suppress a dominant-negative RAS2 mutant. Cell, 65, 1225.
45. PRENDERGAST, G.G., DAVIDE, J.P., DESOLMS, S.J., GIULIANI, E.A., GRAHAM, S L . GIBBS, J.B., OLIFF, A. & KOHL, N.E. (1994). Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Molecular and Cellular Biology, 14, 4193.
46. REINSTEIN, J., SCHLICHTING, I., FRECH, M., GOODY, R.S. & WITTINGHOFER, A. (1991). p21 with a phenylalanine 28-leucine mutation reacts normally with the GTPase activating protein Gap but nevertheless has transforming properties. Journal of Biological Chemistry, 266, 17700.
47. REISS, Y. GOLDSTEIN, J.L., SEABRA, M.C., CASEY, P.J. & BROWN, M.S. (1990). Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 62, 81.
48. SAISON-BEHMOARAS, T., TOCQUE, B., REY, I., CHASSIGNOL, M., THUONG, N.T. & HELENE, C. (1991). Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO Journal, 10, 1111.
49. SCHWAB, G., CHAVANY, C., DUROUX, I., GOUBIN, G., LEBEAU, J., HELENE, C. & SAISON-BEHMOARAS, T. (1994). Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proceedings of the National Academy of Sciences of the USA, 91, 10460.
50. SHIRASAWA, S , FURUSE, M., YOKOYAMA, N & SASAZUKI, T (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science, 260, 85.
51. SIGAL, I.S., GIBBS, J.B., JS, D.A. & SCOLNICK, E.M. (1986). Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proceedings of the National Academy of Sciences of the USA, 83, 4725.
52. SRINIVASAN, S.K. & IVERSEN, P. (1995). Review of in vivo pharmacokinctics and toxicology of phosphorothioate oligonucleotides. Journal of Clinical Laboratory Analysis, 9, 129.
53. STACEY, D.W. & KUNG, H.F. (1984). Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature, 310, 508.
54. STACEY, D W., DEGUDICIBUS, S.R. & SMITH, M R. (1987). Cellular ras activity and tumor cell proliferation. Experimental Cell Research, 171, 232.
55. TAPAROWSKY, E., SUARD, Y., FASANO, O., SHIMIZU, K., GOLDFARB, M. & WIGLER, M. (1982). Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature, 300, 762.
56. TRAHEY, M. & MCCORMICK, F. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science, 238, 542.
57. ULSH, L.S. & SHIH, T.Y. (1984). Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Molecular and Cellular Biology, 4, 1647.
58. WILLUMSEN, B.M. (1992). The ras Transforming Protein. Academic Press: Copenhagen.
59. ZHANG, Y., MUKHOPADHYAY, T., DONEHOWER, L.A , GEORGES, R N. & ROTH, J.A. (1993). Rctroviral Vector-mediated transduction of K.-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Therapy, 4, 451.